23,255 Shares in Sana Biotechnology, Inc. $SANA Acquired by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC bought a new position in Sana Biotechnology, Inc. (NASDAQ:SANA) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 23,255 shares of the company’s stock, valued at approximately $63,000.

A number of other institutional investors and hedge funds also recently modified their holdings of SANA. Savant Capital LLC purchased a new position in shares of Sana Biotechnology in the 2nd quarter valued at $172,000. Nisa Investment Advisors LLC increased its holdings in shares of Sana Biotechnology by 673.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 10,911 shares of the company’s stock valued at $30,000 after acquiring an additional 9,501 shares during the last quarter. WealthPlan Investment Management LLC acquired a new stake in shares of Sana Biotechnology during the second quarter worth $48,000. CWM LLC lifted its holdings in Sana Biotechnology by 125.7% in the second quarter. CWM LLC now owns 86,750 shares of the company’s stock worth $237,000 after acquiring an additional 48,319 shares during the last quarter. Finally, Viewpoint Capital Management LLC lifted its holdings in shares of Sana Biotechnology by 19.1% in the 2nd quarter. Viewpoint Capital Management LLC now owns 28,045 shares of the company’s stock worth $77,000 after purchasing an additional 4,500 shares during the last quarter. Institutional investors and hedge funds own 88.23% of the company’s stock.

Sana Biotechnology Price Performance

Shares of Sana Biotechnology stock opened at $3.53 on Wednesday. Sana Biotechnology, Inc. has a fifty-two week low of $1.26 and a fifty-two week high of $7.30. The firm has a market cap of $940.29 million, a P/E ratio of -3.64 and a beta of 1.94. The firm has a 50 day simple moving average of $4.19 and a 200 day simple moving average of $3.47.

Sana Biotechnology (NASDAQ:SANA) last posted its earnings results on Thursday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.03. On average, sell-side analysts expect that Sana Biotechnology, Inc. will post -1.16 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have issued reports on SANA. HC Wainwright reduced their price target on Sana Biotechnology from $11.00 to $9.00 and set a “buy” rating for the company in a research report on Friday, November 7th. Wedbush raised their price objective on Sana Biotechnology from $5.00 to $6.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. Wall Street Zen raised shares of Sana Biotechnology from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Citizens Jmp upped their price objective on shares of Sana Biotechnology from $5.00 to $8.00 and gave the company a “market outperform” rating in a research note on Thursday, October 30th. Finally, Citigroup restated an “outperform” rating on shares of Sana Biotechnology in a report on Thursday, October 30th. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Sana Biotechnology has a consensus rating of “Moderate Buy” and an average target price of $8.33.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.